Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.

MLA

Liang, Qi, et al. “Coexistence of a Novel NBEA-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Alectinib: A Case Report.” Lung Cancer (Amsterdam, Netherlands), vol. 162, Dec. 2021, pp. 86–89. EBSCOhost, https://doi.org/10.1016/j.lungcan.2021.10.015.

APA

Liang, Q., Xu, H., Liu, Y., Zhang, W., Sun, C., Hu, M., Zhu, Y., Tan, S., Xu, X., Wang, S., & Liu, L. (2021). Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. Lung Cancer (Amsterdam, Netherlands), 162, 86–89. https://doi.org/10.1016/j.lungcan.2021.10.015

Chicago

Liang, Qi, Huanhuan Xu, Yiqian Liu, Weiming Zhang, Chongqi Sun, Meng Hu, Yizhi Zhu, et al. 2021. “Coexistence of a Novel NBEA-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Alectinib: A Case Report.” Lung Cancer (Amsterdam, Netherlands) 162 (December): 86–89. doi:10.1016/j.lungcan.2021.10.015.